Author

Claudia Fischer

University of BaselORCID 0009-0002-3266-9641Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Claudia Fischer1 paper · University of Basel

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 1

Frequent Co-Authors

Anne EugsteriD· 2 shared Benjamin KasendaiD· 2 shared Christoph SchultheißiD· 2 shared Heinz Philipp LaubliiD· 2 shared Mascha BinderiD· 2 shared Matthias PeippiD· 2 shared Andreas Wilfer· 1 shared Brenda BesemeriD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Anne EugsterORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Targeting poorly differentiated thyroid cancer with bispecific antibodies and CAR T cells from the human anti-TSHR autoantibody repertoire

Claudia Fischer, Anne Eugster, Brenda Besemer, Mélanie Buchi, Marcus Bauer, Christoph Schultheiß, Elisa D’Arcangelo, Filip Filipsky, Claudia Wickenhauser, Andreas Wilfer, Kerstin Lorenz, Jens Jakscha, Laurent Müller, Roswitha Köberle-Wührer, Benjamin Kasenda, , Mascha Binder

This paper explores using anti-TSHR autoantibodies to create bispecific antibodies and CAR T cells for treating poorly differentiated thyroid cancer, showing potent in vitro and in vivo activity.

bioRxiv · Oct 20, 2026 · PreprintCancer Biology

IGLV3-21-R110-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia

Claudia Fischer, Shih‐Shih Chen, Johanna Nimmerfroh, Anne Eugster, Simon Stücheli, Christoph Schultheiß, Corinne C. Widmer, Dominik Heim, Benjamin Kasenda, Jakob Robert Passweg, Sebastian Kobold, Lukas Egli, Nicolò Coianiz, Obinna Chijioke, Nicholas Chiorazzi, , Mascha Binder

This study develops bispecific antibodies targeting IGLV3-21R110 to selectively kill high-risk CLL cells while sparing healthy B cells and stem cells.

Haematologica · Sep 11, 2025Peer-reviewedCancer Biology